Actinium Pharmaceuticals: Promising Developments in Targeted Radiotherapies and Strong Financial Position Support Buy Rating
Analyst Jason McCarthy from Maxim Group maintains a Buy rating on Actinium Pharmaceuticals, citing promising developments in targeted radiotherapies, especially the ATNM-400 program, and a strong financial position with a cash runway into 2028. The company shows encouraging preclinical results in cancer models, and upcoming presentations are expected to boost investor interest. H.C. Wainwright also reiterated a Buy rating with a $4.00 price target.
Analyst Jason McCarthy from Maxim Group maintained a Buy rating on Actinium Pharmaceuticals and keeping the price target at $5.00.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Jason McCarthy’s rating is based on Actinium Pharmaceuticals’ promising developments in targeted radiotherapies, particularly with their ATNM-400 program. The company has demonstrated encouraging preclinical results in various cancer models, including lung, prostate, and now breast cancer, which could potentially lead to significant clinical opportunities.
Additionally, Actinium’s financial position is strong, with a cash runway extending into 2028, allowing them to continue advancing their pipeline without immediate financial pressure. The upcoming presentation of preclinical data at the San Antonio Breast Cancer Symposium is expected to further highlight the potential of ATNM-400, capturing investor interest and supporting the Buy rating.
McCarthy covers the Healthcare sector, focusing on stocks such as SCYNEXIS, Neuphoria Therapeutics, and Medicus Pharma Ltd. According to TipRanks, McCarthy has an average return of -19.0% and a 29.78% success rate on recommended stocks.
In another report released on November 17, H.C. Wainwright also reiterated a Buy rating on the stock with a $4.00 price target.
